Literature DB >> 9526059

The effect of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and charybdotoxin (CTX) on relaxations of isolated cerebral arteries to nitric oxide.

H Onoue1, Z S Katusic.   

Abstract

The mechanism underlying smooth muscle relaxations of cerebral arteries in response to nitric oxide is still not completely understood. The present study was designed to determine the role of soluble guanylate cyclase in the relaxations to a nitric oxide/nucleophile complex, diethylaminodiazen-1-ium-1,2-dioate (DEA-NONOate). Rings of canine middle cerebral arteries without endothelium were suspended in Krebs-Ringer bicarbonate solution for isometric tension recording. The levels of guanosine 3',5'-cyclic monophosphate (cyclic GMP) were measured by radioimmunoassay technique. During contractions to uridine 5'-triphosphate (UTP), DEA-NONOate (10(-10) to 10(-5) M) caused concentration-dependent relaxations. Measurements of cyclic GMP levels in cerebral arterial wall demonstrated that DEA-NONOate is a potent stimulator of guanylate cyclase and subsequent formation of cyclic GMP. Increasing concentrations of a selective soluble guanylate cyclase inhibitor, 1H-[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), caused concentration-dependent reduction of both cyclic GMP production and relaxations to DEA-NONOate. Interestingly, in the presence of the highest concentration (3 x 10(-6) M) of ODQ, production of cyclic GMP in response to 10(-6) M of DEA-NONOate was abolished, whereas the same concentration of DEA-NONOate caused almost complete relaxation, suggesting that mechanisms independent of cyclic GMP production may mediate relaxing effect of high concentration of a nitric oxide donor. A selective Ca2+-activated potassium channel blocker charybdotoxin (CTX) significantly reduced relaxations to DEA-NONOate resistant to ODQ, supporting the idea that in cerebral arteries nitric oxide may activate potassium channels independently of cyclic GMP. The results of our study suggest that under physiological conditions, guanylate cyclase is a key mediator of cerebral arterial relaxations to nitric oxide. However, under pathological conditions associated with induction of nitric oxide synthase and increased biosynthesis of nitric oxide (e.g., cerebral ischemia, inflammation, sepsis), mechanisms other than formation of cyclic GMP may be activated. Copyright 1998 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9526059     DOI: 10.1016/s0006-8993(97)01393-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

Review 1.  Protecting against vascular disease in brain.

Authors:  Frank M Faraci
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-18       Impact factor: 4.733

Review 2.  Smooth Muscle Ion Channels and Regulation of Vascular Tone in Resistance Arteries and Arterioles.

Authors:  Nathan R Tykocki; Erika M Boerman; William F Jackson
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

3.  Nitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system.

Authors:  K E Wiley; A P Davenport
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

4.  Inhibitory effect of 4-aminopyridine on responses of the basilar artery to nitric oxide.

Authors:  C G Sobey; F M Faraci
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

5.  Cellular mechanisms underlying nitric oxide-induced vasodilation of descending vasa recta.

Authors:  Aurélie Edwards; Chunhua Cao; Thomas L Pallone
Journal:  Am J Physiol Renal Physiol       Date:  2010-11-17

6.  Cyclic GMP-independent relaxation of rat pulmonary artery by spermine NONOate, a diazeniumdiolate nitric oxide donor.

Authors:  K L Homer; J C Wanstall
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

7.  Characterization of Cecal Smooth Muscle Contraction in Laying Hens.

Authors:  Katrin Röhm; Martin Diener; Korinna Huber; Jana Seifert
Journal:  Vet Sci       Date:  2021-05-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.